Medindia

X

MDS Pharma Services' Global Central Lab to launch Apollo

Tuesday, January 22, 2008 General News J E 4
Advertisement
KING OF PRUSSIA, PA, Jan. 22 /PRNewswire-FirstCall/ - MDS Pharma Services,a leading provider of innovative drug discovery and development solutions,announced today the launch of its proprietary Apollo study management systemdeveloped for its Global Central Lab business. Designed with valuable inputfrom clients, Apollo is a unified, web-based study management tool for secureand transparent tracking of study samples and results. Apollo gives clientsreal-time, worldwide access to their study data virtually anywhere, anytime.

The system strengthens the "chain of custody" - from specimen collectionto central lab receipt, to testing and sample storage - further improving theefficiency and quality of studies managed by MDS Pharma Services. And becausethe system is accessible virtually anywhere, anytime, it will enable MDSPharma Services to respond quickly to changes in client needs and studyrequirements regardless of where the client is or where the work is beingdone.

Apollo provides a single interface for all aspects of protocol management,including protocol specifications, kit building, sample reception and testordering, query identification and resolution, customizable results flagging,report distribution, frozen sample management, data extraction and invoicing.The experience for clients using Apollo will be consistent whether the work isbeing done in MDS sites in China, Singapore, France, Germany, Canada or theUS.

"The Apollo system offers significant benefits to our customers, both interms of efficiency and standardization in study management," said MDS PharmaServices President, David Spaight. "A single, global system with increasedtransparency of processes and data across all our sites will help usconsistently deliver on our brand promise of quality, on-time results. And theApollo system - which is exclusive to MDS Pharma Services - will help toredefine the customer experience allowing studies to start on time, runsmoothly and end on time."

Based on input from client surveys, beta testing, and Lean Sigma processimprovement initiatives at MDS Pharma Services, the Apollo system wasspecifically designed to provide real-time, worldwide access to data. Itenables single study setup and supports MDS Pharma Services' corecompetencies, operating procedures and standards. Built on an Oracle database,the Apollo system is a truly singular database that replaces multiple legacysystems and sub-systems, helping to drive improvements in efficiency andquality across the central laboratory business. Apollo provides for globalstandardization of requisitions, reports, kits, barcode labels, as well asscientific information, and improves the accuracy and speed of samplereception and processing.

The new system provides client study teams a host of features that enablegreater control over all aspects of the study. These features include:

MDS Pharma Services is committed to delivering quality results on time. Weoffer a full spectrum of resources to meet the drug discovery and developmentneeds of the pharmaceutical and biotechnology industries. With numerousfacilities strategically located around the world, we apply advancedscientific and technological expertise throughout the drug discovery anddevelopment process - from lead optimization, pre-IND research, early clinicalresearch (bioequivalence, phases I-IIa) and bioanalysis through to globalclinical development (phases IIb-IV), central lab and centralized cardiacservices. For more information, visit our website at www.mdsps.com.

MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ),a global life sciences company that provides market-leading products andservices that our customers need for the development of drugs and diagnosisand treatment of disease. We are a leading global provider of pharmaceuticalcontract research, medical isotopes for molecular imaging, radiothe
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
FDA Approves Cheetah Reliant(TM) for Noninvasive C...
S
Statement from Slim-Fast